Toxoplasmosis therapeutics market to be worth $1.55 billion by 2019

The toxoplasmosis therapeutics market has been predicted to be worth $1.55 billion by 2019, growing at a compound annual growth rate (CAGR) of 3.9% from 2011.

Toxoplasmosis is a parasitic disease spread through contact with animals and raw meat, and is thought to be carried by up to half of the world's human population. Infection can cause mild, flu-like symptoms, though many individuals experience no illness.

Toxoplasmosis is considered an opportunistic infection because it occurs in individuals who have weakened immune systems. It is estimated that more than 60 million people is the US suffer from toxoplasmosis, however 80-90% of infected patients experience no symptoms because their immune systems prevent the parasite from causing the illness.

The number of people set to suffer from toxoplasmosis is due to rocket in the next few years, however, with current treatments not stepping up to the challenges faced, the market could encounter several problems in the future.

The toxoplasmosis market has seen this rise due to a number of factors including global warming, urbanisation and the subsequent changes in livestock systems.

Treatments with the toxoplasmosis therapeutics market comprise of several drugs often prescribed in combination depending on the severity of the infection and the form of toxoplasmosis. The combination of these drugs is not always well-tolerated by patients, who often experience unpleasant side effects.

For more information on the toxoplasmosis therapeutics market, see the latest research: Toxoplasmosis Therapeutics Market

Follow us on Twitter @CandMResearch